Sarcomas | Specialty

Randall Issues Call for Multidisciplinary Management in Giant Cell Tumor of Bone

June 30th 2020

R. Lor Randall, MD, FACS, discusses the need for multidisciplinary collaboration in GCTB, challenges faced in the space, and directions for future research efforts.

European Panel Recommends Against Pexidartinib for Tenosynovial Giant Cell Tumor

June 27th 2020

The European Medicines Agency’s advisory group, the Committee for Medicinal Products for Human Use, has recommended against the acceptance of the marketing authorization for pexidartinib (Turalio) for the treatment of patients with tenosynovial giant cell tumor.

Dr. Tseng on Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

June 23rd 2020

William W. Tseng, MD, discusses the potential role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma.

LTD Changes Correlate With OS in Localized High-Risk Soft Tissue Sarcoma

June 19th 2020

A percentage change in longest tumor diameter of patients with localized high-risk soft tissue sarcoma who were treated with neoadjuvant chemotherapy was found to correlate with overall survival.

Expert Elucidates the Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

June 19th 2020

Neoadjuvant systemic therapy was found to show a modest benefit in patients with retroperitoneal sarcoma, and the tumor response could be used as an indicator of disease biology to predict survival outcomes after surgery.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

May 31st 2020

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Orthopedic Oncologists Recommended for Consult on Bone Sarcoma Treatment After Osteointegration

May 26th 2020

R. Lor Randall, MD, FACS, discusses the cautions medical oncologists should take for their patients with bone sarcomas who undergo limb preservation with osteointegration, and the importance of keeping orthopedic oncologists in the loop.

Case Study Shows Potential for CDK4/6 Inhibition in Metastatic Osteosarcoma

May 15th 2020

The combination of gemcitabine and ribociclib led to a radiographic and histologic response in a woman with chemotherapy-resistant metastatic CDK6-amplified osteosarcoma

FDA Approves Pomalidomide for Kaposi Sarcoma

May 15th 2020

The FDA has approved pomalidomide for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative.

FDA Issues Complete Response Letter for Avapritinib in Fourth-Line GIST

May 15th 2020

The FDA issued a complete response letter stating it will not approve an application for avapritinib for the fourth-line treatment of patients with gastrointestinal stromal tumor. 

Dr. Trent on the Impact of COVID-19 on the Treatment of Rare Cancers

May 12th 2020

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

TSGCT: Novel Agents and Future Directions in Care

May 8th 2020

Physicians’ Experiences With CSF1 Inhibition in TSGCT

May 8th 2020

CSF1 Inhibition in TSGCT: Managing Adverse Events

May 8th 2020

Targeting CSF1 in Advanced TSGCT

May 8th 2020

Tenosynovial Giant Cell Tumors: Symptom and Pain Management

May 8th 2020

Considerations for Radiation Therapy in TSGCT

May 8th 2020

Local Recurrence in Tenosynovial Giant Cell Tumors

May 8th 2020

TSGCT: Considering Scale of Surgery and Disease Factors

May 8th 2020

What is the Role of Surgery in TSGCT?

May 8th 2020